In-life Chemical Inactivation of Plasmodium Parasites by Cabamiquine Induces Long Lasting Immune Protection

Clicks: 2
ID: 324711
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #422 of 432 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Malaria remains a major global health challenge, and current vaccine strategies provide limited protection. Cabamiquine (CBQ), a Plasmodium translation elongation factor 2 inhibitor, arrests parasite growth during both the liver and blood stages of infection and may promote protective immune responses during controlled parasite infection. METHODS: We evaluated whether CBQ-based infection-and-treatment strategies could induce protective immunity in mouse models of liver- and blood-stage Plasmodium infection. Mice received a single oral dose of CBQ during liver-stage infection or CBQ in combination with pyronaridine during blood-stage infection and were subsequently challenged with homologous or heterologous Plasmodium parasites. RESULTS: CBQ treatment during liver-stage infection induced durable protective immunity against homologous and heterologous sporozoite challenge, reduced disease severity, and was associated with liver-resident memory CD8+ T cells. CBQ administered with pyronaridine during blood-stage infection elicited stage-specific immunity that limited parasitemia and protected against severe malaria following homologous or heterologous challenge. Together, these findings demonstrate that CBQ-based infection-and-treatment can combine effective parasite clearance with induction of protective immune responses following both liver- and blood-stage infections. CONCLUSIONS: CBQ enables in-life chemical inactivation of Plasmodium parasites while promoting long-lasting protective immunity in experimental malaria. These findings provide proof of concept for a simple oral infection-and-treatment strategy that could complement existing malaria vaccination and control approaches.
Reference Key
openalex_W7202176359 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Claudia Demarta-Gatsi, Diana Moita, Diana Fontinha, Raquel Ventura, Helena Nunes‐Cabaço, Thomas Spangenberg, Miguel Prudêncio
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag402
URL
https://doi.org/10.1093/infdis/jiag402
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.